Nick Pizzie Sells 33,000 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CFO Nick Pizzie sold 33,000 shares of Axsome Therapeutics stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $240.09, for a total transaction of $7,922,970.00. Following the completion of the transaction, the chief financial officer directly owned 42,867 shares in the company, valued at approximately $10,291,938.03. The trade was a 43.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Axsome Therapeutics Stock Up 4.5%

AXSM traded up $10.50 during trading on Tuesday, reaching $245.64. The company had a trading volume of 917,980 shares, compared to its average volume of 698,516. The company has a debt-to-equity ratio of 2.27, a current ratio of 1.39 and a quick ratio of 1.32. Axsome Therapeutics, Inc. has a 12 month low of $96.09 and a 12 month high of $246.41. The business’s fifty day moving average price is $204.08 and its 200 day moving average price is $179.27. The company has a market cap of $12.64 billion, a P/E ratio of -65.86 and a beta of 0.61.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The company had revenue of $191.20 million during the quarter, compared to the consensus estimate of $191.10 million. The firm’s quarterly revenue was up 57.4% compared to the same quarter last year. Equities analysts anticipate that Axsome Therapeutics, Inc. will post -2.24 EPS for the current year.

Institutional Trading of Axsome Therapeutics

A number of large investors have recently added to or reduced their stakes in AXSM. Wellington Management Group LLP lifted its stake in Axsome Therapeutics by 84.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock valued at $162,082,000 after purchasing an additional 609,516 shares during the last quarter. First Trust Advisors LP lifted its stake in Axsome Therapeutics by 1,230.2% in the 1st quarter. First Trust Advisors LP now owns 577,479 shares of the company’s stock valued at $97,606,000 after purchasing an additional 534,066 shares during the last quarter. Norges Bank acquired a new stake in Axsome Therapeutics in the 4th quarter valued at about $90,490,000. Price T Rowe Associates Inc. MD lifted its stake in Axsome Therapeutics by 45.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company’s stock valued at $275,763,000 after purchasing an additional 472,422 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in Axsome Therapeutics by 73.3% in the 3rd quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock valued at $120,303,000 after purchasing an additional 419,008 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on AXSM. Oppenheimer set a $280.00 price objective on shares of Axsome Therapeutics in a research report on Monday, May 4th. Guggenheim boosted their price objective on shares of Axsome Therapeutics from $245.00 to $260.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $272.00 price objective on shares of Axsome Therapeutics in a research report on Monday, May 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Monday, April 20th. Finally, Mizuho boosted their price objective on shares of Axsome Therapeutics from $228.00 to $310.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $251.26.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.